Zacks Investment Research downgraded shares of Swedish Orphan Bio Spon (NASDAQ:SWTUY) from a buy rating to a hold rating in a report issued on Saturday morning.

According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “

Swedish Orphan Bio Spon (NASDAQ SWTUY) remained flat at $15.72 during mid-day trading on Friday. The company has a 50 day moving average of $15.72 and a 200 day moving average of $14.85. The company has a market capitalization of $4.23 billion and a PE ratio of 54.39. Swedish Orphan Bio Spon has a one year low of $10.25 and a one year high of $16.49.

TRADEMARK VIOLATION NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/27/swedish-orphan-bio-spon-swtuy-lowered-to-hold-at-zacks-investment-research.html.

Receive News & Stock Ratings for Swedish Orphan Bio Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio Spon and related stocks with our FREE daily email newsletter.